论文部分内容阅读
目的:探讨黄黄芪注射液/华蟾素注射液联合右丙亚胺对阿霉素相关性心脏毒性的保护作用,并与单用右丙亚胺对比研究。方法:120例采用含阿霉素化疗方案首次治疗的恶性肿瘤患者随机分为:A组:右丙亚胺组;B组:右丙亚胺与黄芪注射液联合治疗;C组:右丙亚胺与华蟾素注射液联合治疗组;D组:右丙亚胺与黄芪注射液及华蟾素注射液联合治疗组(每组各30例)。A组常规化疗前给予右丙亚胺静脉输注,B组常规化疗前给予右丙亚胺与黄芪联合治疗,C组常规化疗前给予右丙亚胺与华蟾素联合治疗,D组常规化疗前给予右丙亚胺、黄芪及华蟾素联合治疗,共4个周期。比较4组患者治疗前后心电图、肌酸激酶同工酶(CK-MB)和心肌肌钙蛋白Ⅰ(cTnⅠ),左室舒张末期内径(LVIDD),左射血分数(EF)。结果:经4个周期治疗后,D组无论是心电图异常发生率还是CK-MB、cTnⅠ、LVIDD、EF与另三组比较差异均有显著性(P<0.05);而A、B、C3组间患者的心电图异常发生率、CK-MB、cTnⅠ、LVIDD、EF无显著性差异(P>0.05)。结论:黄芪和华蟾素注射液联合右丙亚胺可减低阿霉素所致心脏毒性作用,优于单用右丙亚胺。
Objective: To investigate the protective effect of Huangguqi injection combined with cinobufagin injection and dexrazoxane on doxorubicin-related cardiotoxicity and to compare with dexrazoxane alone. Methods: One hundred and twenty patients with malignant tumors who were treated with doxorubicin chemotherapy for the first time were randomly divided into group A: dexrazoxane; group B: dexrazoxane and astragalus injection; group C: dex Amine and cinobufotalin injection group; group D: combination of dexrazoxane and astragalus injection and cinobufotalin injection group (30 cases in each group). Group A received routine intravenous dexrazoxane before routine chemotherapy, Group B received combination of dexrazoxane and astragalus before routine chemotherapy, Group C received combination of dexrazoxane and cinobufacine before routine chemotherapy, and Group D received routine chemotherapy Pre-given right-propylamine, Astragalus and cinobufotalin combined treatment, a total of 4 cycles. The electrocardiogram, CK-MB and cTnⅠ, LVIDD and EF were compared between the four groups before and after treatment. Results: After 4 cycles of treatment, the differences of ECG abnormality rate, CK-MB, cTnⅠ, LVIDD and EF between the three groups were statistically significant (P <0.05) There was no significant difference in ECG abnormalities, CK-MB, cTnⅠ, LVIDD and EF between the two groups (P> 0.05). Conclusion: Radix Astragali and cinobufagin combined with dexrazoxane can reduce the cardiotoxicity induced by doxorubicin, which is better than that of dexrazoxane alone.